Indaptus Therapeutics annual return on equity
2021
2022
2023
2024
2025
Indaptus Therapeutics Return on Equity (ROE) Growth & History (INDP)
Indaptus Therapeutics's return on equity was −587.59% for fiscal 2025.
View full Indaptus Therapeutics company overviewIndaptus Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −587.59% | −400.06 pp |
| 2024 | 2024-12-31 | −187.52% | −103.49 pp |
| 2023 | 2023-12-31 | −84.04% | −36.71 pp |
| 2022 | 2022-12-31 | −47.32% | −4.08 pp |
| 2021 | 2021-12-31 | −43.25% | — |
Indaptus Therapeutics quarterly return on equity
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −28.44% | +900.01 pp |
| Q1 2026 | 2026-03-31 | −115.52% | +18.88 pp |
| Q4 2025 | 2025-12-31 | −209.16% | −126.10 pp |
| Q3 2025 | 2025-09-30 | −202.92% | −152.48 pp |
| Q2 2025 | 2025-06-30 | −928.45% | −876.73 pp |
| Q1 2025 | 2025-03-31 | −134.40% | −98.89 pp |
| Q4 2024 | 2024-12-31 | −83.05% | −53.84 pp |
| Q3 2024 | 2024-09-30 | −50.44% | −27.34 pp |
| Q2 2024 | 2024-06-30 | −51.72% | −35.42 pp |
| Q1 2024 | 2024-03-31 | −35.51% | −16.95 pp |
| Q4 2023 | 2023-12-31 | −29.21% | −15.20 pp |
| Q3 2023 | 2023-09-30 | −23.10% | −11.14 pp |
| Q2 2023 | 2023-06-30 | −16.30% | −4.27 pp |
| Q1 2023 | 2023-03-31 | −18.57% | −8.85 pp |
| Q4 2022 | 2022-12-31 | −14.01% | −5.31 pp |
| Q3 2022 | 2022-09-30 | −11.96% | +6.36 pp |
| Q2 2022 | 2022-06-30 | −12.03% | — |
| Q1 2022 | 2022-03-31 | −9.72% | — |
| Q4 2021 | 2021-12-31 | −8.70% | — |
| Q3 2021 | 2021-09-30 | −18.32% | — |
Indaptus Therapeutics return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Indaptus Therapeutics's return on equity decreased from −43.25% to −587.59%, a change of −544.34 percentage points. The latest reported quarter, Q2 2026, shows −28.44%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Indaptus Therapeutics source filings ↗